THEY SAID IT! U.S. SENATE JUDICIARY SUBCOMMITTEE HIGHLIGHTS BIG PHARMA’S ANTI-COMPETITIVE PRACTICES

07-14-2021 Blog Posts

Lawmakers Showcase How Big Pharma’s Patent Abuse Drives Out-of-Control Prescription Drug Prices During a hearing Tuesday before the U.S. Senate Committee on the Judiciary’s Subcommittee on Competition Policy, Antitrust, and Consumer Rights, lawmakers on both sides of the aisle hammered Big Pharma for the industry’s anti-competitive and price-hiking practices. The hearing adds to the growing […]

DOSE OF REALITY: LAWMAKERS TO PROBE BIG PHARMA PATENT ABUSE AS INNOVATION EXCUSES CRUMBLE

07-13-2021 Blog Posts

U.S. Senate Judiciary Subcommittee Hearing Tuesday Will Build on Momentum for Lawmakers to Hold Big Pharma Accountable, Lower Prescription Drug Prices On Tuesday, the U.S. Senate Committee on the Judiciary’s Subcommittee on Competition Policy, Antitrust, and Consumer Rights is set to hold a hearing examining Big Pharma’s egregious anti-competitive practices that drive-up prescription drug prices. […]

BIG PHARMA WATCH: JULY PRICE HIKES CLIMB TO 52

07-7-2021 Blog Posts

Brand Name Drug Companies Stick to Business-as-Usual in Third Major Round of Pandemic Price Hikes In case you missed it, Big Pharma companies are actively engaged in price hikes on branded medications — the industry’s third major round of price increases during the pandemic. So far this month, Big Pharma has hiked prices on 52 […]

BIG PHARMA WATCH: HEADLINES SHOW BIOGEN ADHUHELM PRICING HAS REIGNITED URGENCY TO HOLD BIG PHARMA ACCOUNTABLE

06-25-2021 Blog Posts

Coverage Highlights Backlash Over Massive Price Tag for Unproven Treatment, Cost to Taxpayers and Health System Earlier this month, after the U.S. Food and Drug Administration (FDA) approved brand name drug maker Biogen’s Alzheimer’s treatment aducanumab, brand name Aduhelm, despite serious questions about the medication’s clinical benefit for patients and zero votes in favor of […]

SECOND OPINION: PFIZER’S PHONY CALL FOR LOWER DRUG COSTS

06-22-2021 Blog Posts

CEO Sidesteps Big Pharma’s Pricing Practices; Pushes Proposals That Would Boost Drug Company Profits and Incentivize Price Hikes During a recent interview on Bloomberg’s “Balance of Power,” Pfizer CEO Albert Bourla claimed the pharmaceutical industry is willing to be a helpful partner in reducing “significantly the cost of medicines.” What Bourla did not mention in […]

CSRXP: WYDEN RX PRICING PRINCIPLES ADD TO MOMENTUM IN WASHINGTON TO HOLD BIG PHARMA ACCOUNTABLE

06-22-2021 Blog Posts

Lawmakers Must Advance Solutions to Lower Drug Prices  For Immediate Release Contact: Jon Conradi 860-235-3884 [email protected] Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Tuesday on the release of drug pricing principles from U.S. Senate Committee on Finance Chairman Ron Wyden (D-OR). “CSRxP commends Chairman Wyden for his leadership and dedication to […]

WHAT THEY ARE SAYING: BIOGEN’S “SIMPLY UNACCEPTABLE” ADUCANUMAB PRICING HIGHLIGHTS URGENCY FOR RX SOLUTIONS

06-14-2021 Blog Posts

Broad-based Opposition to Egregious Launch Price on Drug With Unproven Clinical Benefit Adds to Momentum to Hold Big Pharma Accountable Last week, the U.S. Food and Drug Administration (FDA) approved Alzheimer’s treatment aducanumab, brand name Aduhelm, despite serious questions about the medication’s clinical benefit for patients and a unanimous vote against moving forward from the […]

ICYMI: BIG PHARMA’S FASTER-THAN-INFLATION PRICE HIKES COSTING MEDICARE BILLIONS OF DOLLARS

06-7-2021 Blog Posts

AARP Study Finds Brand Name Drug Companies Increased Prices Above Rate of Inflation on 90 Percent of Best-Selling Part D Medications In case you missed it, AARP released a new report Monday detailing how drug price increases that exceed the rate of inflation are costing the Medicare Part D program billions of dollars in additional […]

SECOND OPINION: DEBUNKING BIG PHARMA’S BOGUS INNOVATION RHETORIC

06-7-2021 Blog Posts

For far too long Big Pharma has used the excuse that research and development (R&D) costs justify out-of-control prescription drug prices and that solutions to lower prices threaten innovation into new breakthroughs. These tired arguments, which Big Pharma wields like a shield to protect the industry’s anti-competitive and price-hiking practices, simply don’t hold up to […]

THEY SAID IT! ABBVIE CEO BRAGS ON ABILITY TO HIKE PRICES IN U.S., ADMITS COMPETITION WORKS AND CONFIRMS BIG PHARMA PATENT GAMES DESIGNED FOR “PRICING POWER”

05-19-2021 Blog Posts

House Oversight Lawmakers Commit to Bipartisan Action to Hold Big Pharma Accountable During Explosive Hearing on Out-of-Control Drug Prices During a hearing Tuesday before the U.S. House Committee on Oversight and Reform, the CEO of AbbVie, the manufacturer of the world’s best-selling drug Humira, was put squarely on the hot seat as lawmakers drilled down […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.